Menu

Home

Blog

Private Eye

Bristol Pathology Inquiry

FOI Balls

Books

News

Videos

Biography

Contact

Press Info

Tour Dates

Interview Feature

Press Quotes

Tour Reviews

Merchandise

March 2, 2011

Medicine Balls, Private Eye Issue 1283
Filed under: Private Eye — Tags: , — Dr. Phil @ 10:24 am

Open heart surgery

For more than 60 years, the NHS has pretended it can provide high quality care across the board from cradle to grave and close to home. Politicians, managers and clinical staff have colluded to hide the dangers and inadequacies of an endemically patchy service, and although the massive injection of money under Labour has resulted in improved outcomes for many diseases, no health secretary has had the balls to push through unpopular reorganisations of services that can only be safely and sustainably delivered in fewer, larger units.

So two cheers for NHS Specialised Services and the latest attempt to reduce the number of hospitals providing children’s heart surgery from eleven to six or seven. The Eye has been campaigning for this since breaking the story of the Bristol heart scandal in 1992, the subsequent public inquiry recommended it a decade ago, as did a review of services in 2003. The Labour government, alas, was ‘minded not to agree’, preferring small units to fly by the seat of their pants rather than risk the political fallout from closing them.

Labour hid behind the statistics, claiming that all of the units were performing well, but the figures were too small to provide meaningful comparisons and besides, it’s the process of delivering such specialised care that matters as much as the outcome. As the recent scandal in Oxford showed, a truly gifted individual workaholic surgeon can just about keep a service afloat but when he takes his first holiday in three years and hands over to an unsupervised new recruit, it all falls to pieces.

It’s hard to believe that such a skeleton service could be tolerated in the NHS twenty years after the Eye exposed another, but in the interim, no quality standards have been implemented to ensure all units doing the most complex surgery on hearts the size of a plum have the resources and staffing levels to do it safely. As one eminent surgeon put it: ‘People often joke that if surgeons were like pilots, and we died with our patients, we might take a bit more care. But no pilot would be forced to take off with the tank on empty and half a wing missing. In the NHS, that happens all the time.’

The latest, and hopefully final, review of child heart surgery deserves huge credit not just for finally defining these standards and arguing strongly for a reduction in the number of centres in order to achieve them, but in the transparent manner in which it has visited all of the units, meeting staff, parents, carers and patients. When the case for reform is understood, it’s a no brainer. Larger centres get better and more statistically comparable outcomes, can provide urgent care around the clock, have room to expand as technology advances, allow staff to support and mentor each other (and go on holiday) and will allow the UK to train its own child heart surgeons rather than import them.

A 4 month public consultation starts this week1 before the final outcome is announced. Health Secretary Andrew Lansley has thus far been true to his word and devolved the decision to a panel with an expert knowledge of child heart surgery. Their public meeting, on February 16, was the rarest of occasions when the NHS admitted openly and honestly that it has been winging it for years and it can’t go on pretending to provide safe, high quality specialist care everywhere.

There will doubtless be public demonstrations to protect threatened units, but Lansley must resist the temptation to interfere. All those involved in the delivery of child heart surgery have bought into these reforms, they now have to debate them with the public and reach a final conclusion without the knee jerk posturing of politicians. If it works, it’ll be a huge step forward for child heart surgery and a template for NHS reorganisation. If it doesn’t, I’ll set light to myself outside the department of health.

MD 1 www.specialisedservices.nhs.uk/safeandsustainable



  • D Havercroft

    Well done Phil for your part in keeping up the pressure for all these years.

  • Peter B

    “Larger centres get better and more statistically comparable outcomes”. Show us the evidence, Phil – this is not true for volumes above 150 cases per year or so. The reviews own statistical analysis of the data says as much. The much vaunted ‘Standards’ of the previous reviews and this one are evidence free numbers plucked out of a hat to make sure that certain units continue.

  • leo Voisey

    Stem cells are “non-specialized” cells that have the potential to form into other types of specific cells, such as blood, muscles or nerves. They are unlike “differentiated” cells which have already become whatever organ or structure they are in the body. Stem cells are present throughout our body, but more abundant in a fetus.
    Medical researchers and scientists believe that stem cell therapy will, in the near future, advance medicine dramatically and change the course of disease treatment. This is because stem cells have the ability to grow into any kind of cell and, if transplanted into the body, will relocate to the damaged tissue, replacing it. For example, neural cells in the spinal cord, brain, optic nerves, or other parts of the central nervous system that have been injured can be replaced by injected stem cells. Various stem cell therapies are already practiced, a popular one being bone marrow transplants that are used to treat leukemia. In theory and in fact, lifeless cells anywhere in the body, no matter what the cause of the disease or injury, can be replaced with vigorous new cells because of the remarkable plasticity of stem cells. Biomed companies predict that with all of the research activity in stem cell therapy currently being directed toward the technology, a wider range of disease types including cancer, diabetes, spinal cord injury, and even multiple sclerosis will be effectively treated in the future. Recently announced trials are now underway to study both safety and efficacy of autologous stem cell transplantation in MS patients because of promising early results from previous trials.
    History
    Research into stem cells grew out of the findings of two Canadian researchers, Dr’s James Till and Ernest McCulloch at the University of Toronto in 1961. They were the first to publish their experimental results into the existence of stem cells in a scientific journal. Till and McCulloch documented the way in which embryonic stem cells differentiate themselves to become mature cell tissue. Their discovery opened the door for others to develop the first medical use of stem cells in bone marrow transplantation for leukemia. Over the next 50 years their early work has led to our current state of medical practice where modern science believes that new treatments for chronic diseases including MS, diabetes, spinal cord injuries and many more disease conditions are just around the corner.
    There are a number of sources of stem cells, namely, adult cells generally extracted from bone marrow, cord cells, extracted during pregnancy and cryogenically stored, and embryonic cells, extracted from an embryo before the cells start to differentiate. As to source and method of acquiring stem cells, harvesting autologous adult cells entails the least risk and controversy. 
    Autologous stem cells are obtained from the patient’s own body; and since they are the patient’s own, autologous cells are better than both cord and embryonic sources as they perfectly match the patient’s own DNA, meaning that they will never be rejected by the patient’s immune system. Autologous transplantation is now happening therapeutically at several major sites world-wide and more studies on both safety and efficacy are finally being announced. With so many unrealized expectations of stem cell therapy, results to date have been both significant and hopeful, if taking longer than anticipated.
    What’s been the Holdup?
    Up until recently, there have been intense ethical debates about stem cells and even the studies that researchers have been allowed to do. This is because research methodology was primarily concerned with embryonic stem cells, which until recently required an aborted fetus as a source of stem cells. The topic became very much a moral dilemma and research was held up for many years in the US and Canada while political debates turned into restrictive legislation. Other countries were not as inflexible and many important research studies have been taking place elsewhere. Thankfully embryonic stem cells no longer have to be used as much more advanced and preferred methods have superseded the older technologies. While the length of time that promising research has been on hold has led many to wonder if stem cell therapy will ever be a reality for many disease types, the disputes have led to a number of important improvements in the medical technology that in the end, have satisfied both sides of the ethical issue.
    CCSVI Clinic
    CCSVI Clinic has been on the leading edge of MS treatment for the past several years. We are the only group facilitating the treatment of MS patients requiring a 10-day patient aftercare protocol following neck venous angioplasty that includes daily ultrasonography and other significant therapeutic features for the period including follow-up surgeries if indicated. There is a strict safety protocol, the results of which are the subject of an approved IRB study. The goal is to derive best practice standards from the data. With the addition of ASC transplantation, our research group has now preparing application for member status in International Cellular Medicine Society (ICMS), the globally-active non-profit organization dedicated to the improvement of cell-based medical therapies through education of physicians and researchers, patient safety, and creating universal standards. For more information please visit http://www.neurosurgeonindia.org/